Oak Ridge Investments LLC Lowers Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Oak Ridge Investments LLC cut its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 20.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 61,165 shares of the company’s stock after selling 15,634 shares during the quarter. Oak Ridge Investments LLC’s holdings in UroGen Pharma were worth $651,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its holdings in shares of UroGen Pharma by 263.1% during the 3rd quarter. JPMorgan Chase & Co. now owns 68,062 shares of the company’s stock worth $864,000 after acquiring an additional 49,318 shares during the period. Tidal Investments LLC increased its position in UroGen Pharma by 19.1% during the third quarter. Tidal Investments LLC now owns 37,595 shares of the company’s stock worth $477,000 after purchasing an additional 6,030 shares during the last quarter. Barclays PLC raised its stake in UroGen Pharma by 409.3% during the third quarter. Barclays PLC now owns 59,778 shares of the company’s stock worth $759,000 after purchasing an additional 48,040 shares during the period. Geode Capital Management LLC boosted its holdings in shares of UroGen Pharma by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 455,637 shares of the company’s stock valued at $5,787,000 after purchasing an additional 34,248 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in shares of UroGen Pharma during the 3rd quarter valued at $297,000. 91.29% of the stock is owned by institutional investors and hedge funds.

UroGen Pharma Stock Performance

UroGen Pharma stock opened at $10.27 on Monday. The company has a debt-to-equity ratio of 4.77, a quick ratio of 8.77 and a current ratio of 9.00. UroGen Pharma Ltd. has a one year low of $9.78 and a one year high of $20.70. The stock’s 50 day moving average price is $11.39 and its 200 day moving average price is $13.10. The firm has a market capitalization of $240.83 million, a PE ratio of -3.26 and a beta of 1.09.

UroGen Pharma (NASDAQ:URGN) last announced its earnings results on Wednesday, November 6th. The company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.29. The firm had revenue of $25.20 million during the quarter, compared to analysts’ expectations of $24.22 million. During the same quarter last year, the company posted ($0.68) earnings per share. As a group, sell-side analysts expect that UroGen Pharma Ltd. will post -3.1 EPS for the current fiscal year.

Wall Street Analyst Weigh In

URGN has been the subject of a number of research reports. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Wednesday, January 15th. HC Wainwright reiterated a “buy” rating and set a $60.00 target price on shares of UroGen Pharma in a report on Tuesday, October 15th. EF Hutton Acquisition Co. I upgraded shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Finally, Oppenheimer reiterated an “outperform” rating and set a $40.00 price objective on shares of UroGen Pharma in a research note on Wednesday, October 16th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $43.70.

UroGen Pharma Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.